Floatz logo

ANTI-CD47/CD19 BISPECIFIC MONOCLONAL ANTIBODY TG-1801

Marginal Zone Lymphoma

TG Therapeutics, Inc.monoclonal_antibodyPhase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

106 Active assets in the Marginal Zone Lymphoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
University of Miami
Phase 2BBB
Orelabrutinib
Henan Cancer Hospital
Phase 4BBB
Fludarabine
Paolo Caimi, MD
Phase 2BBB
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2BBB
VINCRISTINE SULFATE
Mayo Clinic
Phase 2BBB

View all 50 →

Same molecule, other indications

ANTI-CD47/CD19 BISPECIFIC MONOCLONAL ANTIBODY TG-1801 is also rated in:

Richter transformationDormant
CC
Indicative ·
43 / 100
View asset →
Indolent LymphomaDormant
CC
Indicative ·
43 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →